Gene Modification
Intellia’s CRISPR Gene Editing Therapy Shows Promising Results in Reducing HAE Attacks
Intellia Therapeutics, CRISPR Gene Editing, Hereditary Angioedema (HAE), NTLA-2002, Clinical Trials, Gene Therapy, Rare Diseases
Prime Medicine Partners with Bristol Myers Squibb in $3.5B Cell Therapy Deal, Narrows Pipeline Focus
Prime Medicine, Bristol Myers Squibb (BMS), Cell Therapy, Gene Editing, Prime Editing, PASSIGE Technology, Ex Vivo T-Cell Therapies, Pipeline Reprioritization, Strategic Collaboration
Tome Biosciences, a High-Profile Gene Editing Startup, Announces Massive Layoffs and Sale Plans
Tome Biosciences, gene editing, layoffs, startup, biotech, financial struggles
Tome Biosciences Halts Operations Amid Financial Strains, CEO Focuses on Strategic Deals
Tome Biosciences, gene editing, layoffs, financial struggles, strategic options, Rahul Kakkar
Gene Editing Biotech Tome Scales Back Operations Despite $213M Funding Round
Gene editing, biotech, Tome, funding, investor sentiment, layoffs, reorganization
Metagenomi Shifts Focus from ALS to Kidney Disease, Seeks New Partners
Metagenomi, ALS, kidney disease, gene editing, base editing, RIGS, Metagenomi drops ALS program, new kidney disease partner
Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million
Novo Nordisk, 2seventy, gene editing, haemophilia, MegaTAL, in vivo gene editing technology
CRISPR Gene Editing Therapy Can Be Administered Twice, Intellia Study Suggests
CRISPR, gene editing, Intellia Therapeutics, transthyretin amyloidosis, gene therapy, re-dosing
Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership
Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval
Intellia Therapeutics Advances in Hereditary Angioedema Treatment with Durable One-Dose CRISPR Gene Editing Therapy
Intellia Therapeutics, Hereditary Angioedema (HAE), CRISPR Gene Editing, NTLA-2002, Single-Dose Treatment, Long-Term Data, Clinical Trials